Business Model
HCE provides consulting services for contract manufacturing, technology transfers, joint ventures, and portfolio management for small and large molecule development and commercialization. These products and services are placed with small, medium and large manufacturers keen to enter and expand within the biotech and pharmaceutical markets. HCE will link FDA and EMA approved manufacturers of both bulk and finished pharmaceuticals with business partners in search of these products to commercialize and capture market share.
Our Services
Product Candidate Acquisition
Product Candidate Acquisition
premedia services
preclinical research services
Core competencies at Healthcare Economics
IP and Technology Evaluation
HCE has proven experience in technology assessment, valuation and determining pricing for intellectual property.
Strategic Alliances
Many firms are actively seeking partners to develop a strategic alliance whereby each firm agrees on a specific set of objectives and goals to form collaborations.
In-Out Licensing
Many firms will find it compelling and advantageous to in-license or out-license products within various stages of development.
Merger and Acquisition Support
HCE will drive value throughout the deal lifecycle providing strategic merger and acquisition (M&A) and divesture support starting from due diligence, through valuation and culminating in deal closure.
Industries
During 2010 -2017 and during 2019-2024 approximately USD $150B and $198B respectively either have been and or are at risk of losing patent protection.
HCE will utilize its resources in a similar manner as that employed within the biotechnology segment. In many instances pharmaceutical firms are seeking additional
